end market pressur lead estim cut
driver upsid somewhat unclear
execut market tumult upsid lever unclear
amerisourcebergen solid entir portfolio saw steadi growth aid
increment pull-forward script demand due covid guidanc reduct
appear mostli unsurpris well theme drive lower guidanc
necessarili new one time rx growth anim health demand pressur etc
frame downsid clearli help drive share higher post-result still
continu see limit earn upsid fundament basi sure
contempl benefit low-leverag balanc sheet term capit
deploy contribut therefor reiter under-perform rate price
object simpli prefer risk/reward group vs
po base price-to-earnings vs price-to-earnings previous
ep covid impact slightli higher year opex
reduc ep ep
reduct account beat also growth moder
across segment off-set slightli lower opex growth reduct
incorpor demand recoveri specialti particular also higher opex vs
previou model growth similar level
upcom event catalyst
rest distributor continu look sign
turnaround script sales/volum trend given recent growth declin across variou
channel weekli rx tracker link addit await color brand price
increas gener price dynam regulatori legisl chang
come month one newer element manufactur activ anim health
channel await see comment evalu direct sale
mean ah distributor final opioid litig remain question
entir channel manufactur includ on-going delay due
full definit iqmethod sm measur see page
bofa secur seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
one largest drug distributor us
sizabl global gener sourc joint ventur
partnership
anim health unit oper
companion product anim distribut
transport logist technolog
compani base chesterbrook pa
under-perform rate driven uncertainti
around core distribut profit growth
profit squeez across pharma suppli
chain subsector would expect distributor like
whose pharmaci struggl
reimburs pressur feel
squeez addit expect
continu premium cah/mck see
spread close
adj ebit
benefit growth largest custom growth specialti
distribut overal market growth
increas pharmaceut demand quarter result higher
revenu gp also incur elev oper expens
adj ebit
driven gross profit growth mwi world courier off-set part
higher opex
march quarter benefit pharmedium exit
higher expect cash balanc expect signific benefit
interest remaind year
repurchas share ytd
adj track full year
revenu lsd-msd rang
adj ep
pharma adj ebit lsd-msd rang
adj ebit declin lsd rang prev hsd growth
april trend encourag sale growth full line distribut oncolog
non oncolog saw signific weekli sale declin began soften end
month
mwi impact lower volum
dd ep declin due march pull forward pharma sale return ep
growth
guidanc assum higher magnitud increas bad debt
expect outstand
think pharmaceut util look back
shift trend specialti trend
telehealth seen year acceler month
e-commerce go import move forward
benefit divers custom base
seen new patient start slow specialti
color around magnitud time weak distribut channel
referr patient visit impact
expect settl activ resum social distanc eas
updat take balanc sheet opioid litig
prioriti intern reinvest open
real updat opioid litig
share repurchas announc new share repurchas
author increas dividend januari
dd declin come
anim health mwi impact companion
anim impact social distanc
product also impact substanti reduc sale
impact protein bottleneck headlin
pull forward mwi anim health revenu begin covid-
product anim impact demand also suppli chain
histor exposur flu vaccin outlook color around pull forward
revenu gross profit pull forward elev cost
oper incom impact
expect increas demand flu vaccin
price object base ep previous
ep multipl five-year averag five-year
high although would argu artifici high due period gener
inflat also repres bigger discount vs last five year
think discount warrant given incorpor modest growth slowdown
seen rest suppli chain well encompass competit
upsid risk po potenti volum pickup increas buyside/sellsid
spread opportun cost save deepen relationship
walgreen largest custom downsid risk po increment wors
drug price pressur increas competit creat gross profit headwind risk
amazon anoth disrupt forc enter suppli chain market on-going
uncertainti headlin relat opioid litig process lack avail
attract capit deploy opportun market volatil tie
outbreak potenti govern intervent drug price control
price object ep multipl five-year
averag discount incorpor margin price pressur
pharmaceut segment slow brand inflat increas competit
downstream independ buy group discount medic segment
incorpor grow risk non-tradit distributor
upsid risk po potenti volum pickup increas buyside/sellsid
spread faster-than-expect contribut recent acquir medic
busi capit deploy downsid risk po increment wors
drug price pressur increas competit creat gross profit headwind risk
amazon anoth disrupt forc enter suppli chain market on-going
uncertainti headlin relat opioid litig process medic
revenue/profit shortfal relat surgic gown kit recal potenti
price object base roughli ep estim multipl
five year averag five year high also
repres bigger averag discount vs last year discount
incorpor modest growth slowdown seen within well rest
pharma suppli chain group
downsid risk po increment wors drug price pressur increas
competit creat gross profit headwind risk amazon anoth disrupt
forc enter suppli chain market on-going uncertainti headlin relat
opioid litig process lack avail attract capit deploy
opportun upsid risk potenti volum pickup increas buyside/sellsid
spread opportun cost save capit deploy contribut
michael cherni herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
qualiti earn
iqmethod smi set bofa global research standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa global research
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
